Turco becomes CMO at Covidien
Mark A. Turco, MD, former director of cardiac and vascular research at Washington Adventist Hospital in Takoma Park, Md., has accepted the position of chief medical officer (CMO) at Covidien within its vascular therapies unit.
Turco has worked as an interventional cardiologist for 10 years at Adventist. He told Cardiovascular Business: “It has been a true privilege to care for my many patients, but I very much look forward to my new role. I'm very excited about making my transition to a CMO role with Covidien. The opportunity to try and impact a larger number of patients and the excitement of building a device portfolio within the organization to become a leader in vascular therapies and impact many disease states led to my career change decision."
Covidien’s vascular therapies unit was recently bolstered by the $2.6 billion acquisition of ev3, which focuses on technologies to treat peripheral vascular and neurovascular diseases.
Turco has worked as an interventional cardiologist for 10 years at Adventist. He told Cardiovascular Business: “It has been a true privilege to care for my many patients, but I very much look forward to my new role. I'm very excited about making my transition to a CMO role with Covidien. The opportunity to try and impact a larger number of patients and the excitement of building a device portfolio within the organization to become a leader in vascular therapies and impact many disease states led to my career change decision."
Covidien’s vascular therapies unit was recently bolstered by the $2.6 billion acquisition of ev3, which focuses on technologies to treat peripheral vascular and neurovascular diseases.